Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

IRM discloses new GPR119 receptor modulators

Feb. 23, 2011

Merck presents new SCD1 inhibitors for metabolic and other disorders

Feb. 22, 2011

Merck Frosst discloses new acyl-CoA desaturase inhibitors

Feb. 22, 2011

Bayer presents new progesterone receptor antagonists

Feb. 22, 2011

FDA requires boxed warning for terbutaline for preterm labor

Feb. 22, 2011

Vitae Pharmaceuticals claims new 11-beta-HSD1 inhibitors

Feb. 21, 2011

Roche patents new activators of glucokinase

Feb. 21, 2011

Regulating adenosine signaling improves symptoms of sickle cell disease

Feb. 21, 2011

Raptor Pharma reopens enrollment in phase III DR Cysteamine trial in nephropathic cystinosis

Feb. 16, 2011

Lundbeck donates certain rights regarding Lu-AE58479 to NINDS

Feb. 16, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...